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 Summary 
Acute rheumatic fever (ARF) is rare in most developed countries, but rates among 
Aboriginal and Torres Strait Islander people are among the highest in the world based on 
available data. Rheumatic heart disease (RHD), which can be prevented by adequate 
treatment of ARF, also occurs at very high rates among Aboriginal and Torres Strait Islander 
people. 
In 2009, the Australian Government’s Rheumatic Fever Strategy was established to improve 
detection, monitoring and management of ARF and RHD through register-based control 
programs in the Northern Territory, Western Australia and Queensland.  
Key findings 
Jurisdictional incidence of ARF and prevalence of RHD: 
Data on the jurisdictional incidence of ARF and prevalence of RHD come from the Northern 
Territory, Queensland and Western Australian Rheumatic Heart Disease registers. It is not 
possible to directly compare these data as the registers are at different stages of 
establishment and coverage. 
• There were 317 recorded cases of ARF in the Northern Territory between 2005 and 2010, 
178 in Queensland between 2009 and 2011, and 21 in Western Australia between 1 July 
2010 and 30 June 2011. 
• There were 1,479 recorded cases of RHD in the Northern Territory (at 31 December 
2010), 939 in Queensland (at 27 August 2012), and 158 in Western Australia (at 30 June 
2011). 
Large inequalities exist between Indigenous and other Australians: 
• Almost all cases of ARF recorded in the Northern Territory between 2005 and 2010 were 
for Aboriginal and Torres Strait Islander people (98%), with 58% in 5–14 year olds. 
• In the Northern Territory in 2010, the prevalence rate of RHD among Aboriginal and 
Torres Strait Islander people was 26 times the rate for non-Indigenous people. 
• Between 2007–08 and 2009–10, Aboriginal and Torres Strait Islander people had 
hospitalisation rates for ARF/RHD that were more than 6 times as high as for other 
Australians, but were less likely to have heart valve surgery if hospitalised. 
• The death rate from RHD among Aboriginal and Torres Strait Islander people was 5 
times as high as that of non-Indigenous Australians between 2004 and 2007. 
RHD is a serious disease and has a substantial impact on individuals:  
• Regular, long-term antibiotic treatment is recommended for people with ARF or RHD. 
The proportion of patients in the Northern Territory who received more than 80% of 
their required doses improved from 23% in 2005 to 28% in 2010, though it still remains 
quite low. 
• Heart surgery may be required to repair heart valve damage resulting from RHD. This is 
likely to explain why 68% of the hospitalisations for ARF/RHD in 2009–10 occurred in 
people aged 55 and over. 
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 1 Introduction 
1.1 Background 
What is acute rheumatic fever? 
Acute rheumatic fever (ARF) is the body’s autoimmune response to an untreated group  
A streptococcus (GAS) bacterial infection of the upper respiratory tract and possibly of the 
skin. The immune-mediated damage caused by ARF can affect the heart, joints, brain, skin 
and subcutaneous tissues (Parnaby & Carapetis 2010). While the acute episode of ARF can be 
extremely painful and sometimes requires hospitalisation, it causes no lasting damage to the 
brain, joints or skin. However, it can cause permanent damage to the heart, particularly the 
mitral and aortic valves, and when this occurs it is known as rheumatic heart disease (RHD). 
The risk of ARF recurrence is relatively high after an initial episode and repeated episodes 
increase the chance of long-term heart valve damage (RHD Australia 2012). 
ARF most commonly occurs in children aged 5–14 but recurrent cases can occur in people 
aged in their mid-forties and older (Carapetis et al. 2005a). Not everyone is susceptible, with 
some evidence to suggest that less than 6% of people in any population have an inherent 
susceptibility (Carapetis et al. 2000). Further, not all strains of GAS are able to cause ARF in a 
susceptible host (RHD Australia 2012). In Australia, ARF is a significant cause of disease 
among Aboriginal and Torres Strait Islander people but occurs very rarely in other 
populations (RHD Australia 2012). 
Correct diagnosis and early treatment of GAS pharyngitis can prevent some cases of ARF 
that may otherwise have developed. To date, a swab test of the throat is usually viewed as 
the gold standard for diagnosing GAS pharyngitis. One limitation of this method is that it 
takes more than 24 hours to confirm the diagnosis if traditional culture techniques are used, 
although rapid tests that can be used at the point of swabbing may improve the timing 
(although they have yet to be used widely in Australia). Although research suggests that 
many cases of ARF could be prevented if people with sore throats due to GAS are treated 
with antibiotics within 9 days of onset, it is not clear that this strategy would reduce the risk 
of ARF in high-risk populations (RHD Australia 2012) because most cases of ARF do not 
follow a sore throat due to GAS infection. 
There is no specific laboratory test for diagnosing ARF so diagnosis is based on clinical 
criteria—the Jones criteria and more recently the World Health Organization (WHO) criteria 
(RHD Australia 2012). The 2012 Australian guidelines for diagnosing ARF are based on a 
modified version of the Jones and WHO criteria that takes into account Australia’s high-risk 
groups, particularly Aboriginal and Torres Islander people. These updated Australian 
guidelines are described in Appendix D (Table D1). 
Once a diagnosis of a first episode or recurrence of ARF is suspected, the patient should be 
admitted to hospital to ensure that all investigations are performed and to confirm the 
diagnosis (RHD Australia 2012). One of the main aims of the management of ARF is to 
prevent further recurrences by use of regular secondary prophylaxis (that is, secondary 
prevention) with benzathine penicillin G (BPG), which has been shown to be the only 
clinically effective and cost-effective RHD control strategy at both community and 
population levels (RHD Australia 2012). More information about secondary prophylaxis for 
ARF and RHD control is in Chapter 5.  
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 What is rheumatic heart disease? 
RHD manifests as permanent damage to the heart muscle or heart valves as a result of ARF. 
Such damage can reduce the ability of the heart to pump blood effectively around the body, 
leading to symptoms such as shortness of breath after exercise and feelings of fatigue and 
weakness. Severe forms of the disease can result in serious incapacity or even death. The 
diagnosis guidelines for RHD are described in Appendix D Table D2. 
Heart valve damage is a common presentation of RHD, often in the form of stenosis or 
regurgitation. Stenosis occurs when a heart valve becomes smaller and stiffer, obstructing 
the flow of blood. Regurgitation occurs when a valve fails to close properly and some blood 
flows back into the heart instead of around the body, increasing the workload of the heart 
and reducing its output. Symptoms of both stenosis and regurgitation include shortness of 
breath on exertion, weakness and fatigue. Mitral regurgitation is the most common occurring 
valve lesion in RHD.  
These symptoms of RHD can also occur with other heart conditions, making a definitive 
diagnosis more difficult. Signs of damage detected by echocardiography and a history of 
ARF are both important clinical indicators for RHD diagnosis.  
The best practice guidelines for managing RHD include access to culturally appropriate 
primary care services; secondary prophylaxis with penicillin; adequate monitoring of 
anticoagulation therapy in patients with atrial fibrillation and/or mechanical prosthetic 
valves; access to oral healthcare; access to echocardiography; access to a specialist physician, 
paediatrician and/or cardiologist, preferably the same specialist, for regular follow-up visits; 
and access to cardiothoracic and interventional cardiology services (RHD Australia 2012). 
Risk factors and prevention of acute rheumatic fever and rheumatic 
heart disease 
GAS infection is a major risk factor for the development of ARF and any factors that would 
increase individual exposure to these bacteria contribute to the risk of ARF. Both untreated 
ARF and the recurrence of ARF are major risk factors for RHD. In addition to GAS throat 
infection, it has been suggested that pyoderma (a GAS skin infection that is often secondary 
to scabies) may also be a risk factor for ARF, particularly among Indigenous communities 
living in a tropical climate (McDonald et al. 2004). Exposure to GAS is closely related to 
overcrowded housing, a low level of hygiene and poor sanitation.  
Socioeconomic and environmental factors play an important, but indirect role, in the 
magnitude and severity of ARF and RHD. A shortage of resources for providing good 
quality health-care services, inadequate knowledge and experience of health-care providers, 
and a low level of awareness of ARF in the community can have a significant impact on the 
early detection of ARF and the development of further complications (WHO 2004). 
Poor socioeconomic conditions, overcrowding and poor sanitation exist in some Aboriginal 
and Torres Strait Islander communities, contributing to the spread of GAS bacterial 
infections and scabies, and so potentially to the development of ARF (Australian Health 
Ministers’ Advisory Council 2011). In addition, the lack of access to medical care, such as in 
some remote communities, increases both the likelihood of recurrent episodes of ARF and of 
ARF progressing to RHD.  
ARF has almost disappeared in the non-Indigenous populations of developed countries, 
mainly due to improvements in living conditions (Quinn 1989). The cases of RHD that 
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 remain in these populations occur mostly among the elderly—a legacy of the higher 
childhood rates of ARF in developed countries before the 1960s. However, high rates of RHD 
still exist in many developing countries, and in Australia the prevalence of RHD is very high 
among Aboriginal and Torres Strait Islander people. 
Implementing the intensive treatment regimens required for long-term prevention of ARF 
and RHD has proven difficult in Australia’s remote Indigenous communities. Current 
guidelines recommend that secondary prevention of RHD requires a 4-weekly injection of 
penicillin to be given for at least 10 years (RHD Australia 2012). In communities where 
socioeconomic disadvantage and lack of access to medical services are commonplace, 
effective prevention, diagnosis and treatment of the disease remain ongoing challenges. 
How Australia compares 
Most of the international studies documenting the incidence of ARF and prevalence of RHD 
have been conducted in school-age children aged 5–14 (Carapetis et al. 2005b). Rates of ARF 
and RHD are high in Aboriginal and Torres Strait Islander children aged 5–14 compared 
with other Australian children and non-Indigenous children of the same age from other 
developed countries (Carapetis et al. 2005b). For more information, see Chapter 6. 
Why is it important to understand acute rheumatic fever and 
rheumatic heart disease? 
ARF and RHD are important to understand and investigate because they are preventable 
diseases. There are two patterns of ARF and RHD observed that are relevant to the health of 
the Australian community. The first, and most important, is that large inequalities exist in 
the occurrence of ARF between Aboriginal and Torres Strait Islander people and other 
Australians. The second consequence is that health problems related to RHD remain among 
our older population (that is, those aged 65 and over) for both Indigenous and other 
Australians, due to higher rates of ARF across the whole population when that generation 
was younger. This can result in the need for significant medical procedures, including heart 
valve replacements for a considerable number of people each year. For example, about 1,200 
people aged 15 and over who were hospitalised with a principal diagnosis of ARF or RHD in 
2009–10 had at least one heart valve procedure performed.  
There has been recent investment in ARF and RHD as a result of the Australian 
Government’s 2008-09 Budget measure ‘New Directions: An equal start in life for Indigenous 
children’ that included funding for a Rheumatic Fever Strategy. The strategy aims to 
improve detection, monitoring and management of ARF and RHD in Aboriginal and Torres 
Strait Islander communities through register-based control programs in the Northern 
Territory, Western Australia and Queensland. The control programs provide education and 
training for health-care providers, families and communities and support improved delivery 
of secondary prophylaxis and clinical care. A national coordination unit—RHD Australia— 
was also established under the strategy to develop a data collection and reporting system, 
and to support improvements in the diagnosis and clinical treatment of ARF and RHD. 
Demographics of Aboriginal and Torres Strait Islander people  
As ARF and RHD are more common in the Indigenous population in Australia, it is 
important to understand the demographics of this population. In 2010, it was estimated there 
were about 563,100 Aboriginal and Torres Strait Islander people in Australia, representing 
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 2.6% of the Australian population (AIHW 2011a). The Northern Territory had the highest 
proportion of Indigenous Australians (29.8%) in 2010, followed by Tasmania (4.0%), 
Queensland (3.6%) and Western Australia (3.3%), while Victoria had the lowest (0.7%). 
However, the majority of Aboriginal and Torres Strait Islander people live in New South 
Wales (29% of the total Australian Indigenous population), Queensland (29%), Western 
Australia (14%) and the Northern Territory (12%).  
As a population group, Indigenous Australians are significantly younger than other 
Australians. For example, Aboriginal and Torres Strait Islander people aged under 15 
constitute 35% of the total Indigenous population, whereas this age group represents about 
19% of the total Australian population. Conversely, those aged 65 and over comprise only 
3% of the Indigenous population, compared with 14% of the total Australian population 
(AIHW 2011a). 
1.2 Aims 
The aims of this report are to present the latest available data on the incidence of ARF (the 
number of new and recurrent cases reported for a given period), the prevalence of RHD (the 
number of existing cases at a given time), and hospitalisations and deaths for ARF and RHD 
in Australia. In particular, this report examines and presents data on: 
1. The incidence of ARF and the prevalence of RHD in Australia. 
2. The demographic characteristics (age, sex and Indigenous status) of those hospitalised 
with, and who die from, ARF and RHD.  
3. Hospitalisation rates for ARF and RHD, and death rates for RHD, by state and territory. 
4. The main hospital procedures performed for ARF and RHD. 
5. International comparisons of hospitalisation and death rates for ARF and RHD. 
1.3 Data sources and methods  
The main data sources used in this report are the AIHW National Hospital Morbidity 
Database; the AIHW National Mortality Database and AIHW GRIM (General Record of 
Incidence of Mortality) Books; Northern Territory, Queensland and Western Australian ARF 
notifications data; data from the Northern Territory, Queensland and Western Australian 
Rheumatic Heart Disease registers; and the AIHW Disease Expenditure Database. Further 
information about the national data sources analysed in this report is in Appendix B. Further 
information about ARF notifications data and the Northern Territory, Queensland and 
Western Australian Rheumatic Heart Disease registers is in Chapter 2. The statistical 
methods used in this report are described in Appendix C. 
What’s missing from the picture? 
Consistent national data on the incidence of ARF and the prevalence of RHD are not 
available. The majority of data currently available are drawn from the Northern Territory, 
Queensland and Western Australia where ARF is a notifiable disease and where register and 
control programs have been established. The development of specifications for a minimum 
data set and a data collection system by RHD Australia in partnership with the jurisdictional 
RHD programs will further support detection and management of ARF and RHD. 
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 2 Acute rheumatic fever 
2.1 Incidence 
It is not possible to give a complete picture of ARF in Australia as no national incidence data 
exist. However, jurisdictional data are available from the Northern Territory, Queensland 
and Western Australian Rheumatic Heart Disease registers. In addition, ARF has been a 
notifiable disease in the Northern Territory since 1994 (RHD Australia 2012), and it became a 
notifiable disease in Queensland in 1999 (Queensland Health: Sweeny & Beard 2009) and in 
Western Australia in September 2007 (Western Australia Department of Health 2012). ARF is 
not a notifiable condition in any other jurisdiction in Australia (RHD Australia 2012). 
Acute rheumatic fever notifications 
In the Northern Territory, all new and recurrent cases of ARF are notified to the Centre for 
Disease Control by doctors and the data are published quarterly in The Northern Territory 
Disease Control Bulletin. In Queensland, confirmed new and recurrent cases of ARF are 
notified to, and published by, Queensland Health. Similarly, all new and recurrent cases of 
ARF in Western Australia are notified to the Western Australian Department of Health’s 
Notifiable Infectious Disease Database and published regularly. 
Northern Territory 
Over the 15 years from 1996 to 2010, there were 823 cases of ARF notified in the Northern 
Territory, at an average rate of 26 notifications per 100,000 population per year. However, the 
annual rate of notifications varied considerably over this period. Notification rates were 
reasonably stable at 24 to 25 notifications per 100,000 population between 1996 and 1999 
before dropping to their lowest level over the 15 years in 2000 (14 notifications per 100,000 
population) (Figure 2.1). There was a sharp increase in notification rates between 2000 and 
2002 (42 per 100,000) followed by a fall between 2002 and 2005 (23 per 100,000). Another 
sharp increase in rates occurred between 2005 and 2007 (38 per 100,000) but rates then fell 
again in 2008 (22 per 100,000). Notification rates have risen slightly since 2008, with the rate 
in 2010 being 26 per 100,000 population. 
Dr Keith Edwards from the Northern Territory Rheumatic Heart Disease Control Program, 
at the Centre for Disease Control, Northern Territory Department of Health, suggested that 
one explanation for the peak in notification rates in 2007 is that an audit in that year found 30 
to 40 clients who were not on the RHD register and these patients were all added at once (K 
Edwards 2012, pers. comm., 5 May). If the date of onset of ARF of most of these patients was 
actually before 2007 then the notification rate in 2007 would be lower than 38 per 100,000 
population. 
Dr Edwards also advised that the penicillin Bicillin® L-A, which is used in the secondary 
prevention of ARF, was temporarily out of stock in 2007. Although patients with ARF and 
RHD were protected by receiving a different form of benzathine penicillin instead, patients 
with skin sores who did not have ARF or RHD may not have received benzathine penicillin, 
and this may have caused an increase in GAS skin disease that, in turn, may have caused 
more cases of ARF (K Edwards 2012, pers. comm., 5 May). 
It is possible that the sharp increase in notification rates between 2000 and 2002 coincided 
with increased awareness of ARF in the Northern Territory after the establishment of the 
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 RHD register in Central Australia. Educational campaigns by clinicians at various times over 
the 15 years might also explain fluctuations in ARF notification rates over time.  
 
Sources: Western Australia Department of Health 2012; Queensland Health 2006, 2008, 2012; Queensland Health: Sweeny & Beard 2009; 
Northern Territory Centre for Disease Control 1998, 2002, 2003, 2004, 2005, 2006, 2007, 2008, 2009, 2010, 2011; Queensland Health 2012; 
Territory Health Services 1999, 2000, 2001. 
Figure 2.1: Acute rheumatic fever notifications, Northern Territory, Queensland and Western 
Australia, 1996–2011 
Queensland  
Between 1999 and 2011, there were 502 cases of ARF notified in Queensland at an average 
rate of 1.0 per 100,000 population per year. ARF notification rates in Queensland between 
1999 and 2011 based on the total Queensland population were much lower than the 
corresponding rates in the Northern Territory (Figure 2.1). However, it should be noted that, 
over this period, Aboriginal and Torres Strait Islander people accounted for about 3% of the 
Queensland population, compared with 30% in the Northern Territory. Therefore, given that 
most cases of ARF occur in Aboriginal and Torres Strait Islander people, notification rates in 
Queensland would be considerably higher if calculated based on the Aboriginal and Torres 
Strait Islander population. 
While there has been some fluctuation in ARF notification rates in Queensland over the  
13 years, overall the rate increased from 0.5 to 1.5 notifications per 100,000 population 
(Figure 2.1). As with the fluctuations in the Northern Territory, the rise in Queensland after 
2009 might be explained by increased awareness of ARF after the establishment of the 
Queensland Rheumatic Heart Disease Register and Control Program register in 2009, while 
the fluctuations before this might be explained by educational campaigns by clinicians at 
various times. Further, Queensland Health introduced a process for routinely looking for 
missed cases of ARF at the end of 2004 and, in 2006, a North Queensland Rheumatic Heart 
Disease Program Coordinator was recruited. These initiatives are likely to have contributed 
to the 41% increase in the number of ARF notifications in North Queensland between 1999–
2004 and 2004–2009 (Hanna & Clark 2010). 
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 Western Australia  
Since September 2007 when ARF became a notifiable disease in Western Australia, 50 cases 
have been notified. Between 2008 and 2011, the ARF notification rate increased from 0.3 to 
0.9 per 100,000 population (Figure 2.1). ARF notification rates in Western Australia between 
2008 and 2010 were much lower than the corresponding rates in the Northern Territory and 
were also lower than the corresponding rates in Queensland (Figure 2.1). 
Northern Territory, Western Australian and Queensland Rheumatic 
Heart Disease Control Program registers 
The Northern Territory Rheumatic Heart Disease Control Program register was established 
in the Top End of the Northern Territory (Darwin) in 1997 and in Central Australia (Alice 
Springs) in 2000 (Noonan et al. 2001; Parnaby 2011). In 2007, the two registers were 
amalgamated into a single register for the Northern Territory. The Northern Territory 
register includes data related to ARF and RHD diagnosis, hospitalisations, compliance with 
prophylactic antibiotic treatment, clinical progress, surgery and deaths. The register is run by 
the Northern Territory Department of Health. Confidentialised data from the register were 
provided to the Australian Institute of Health and Welfare (AIHW) for analysis.  
Queensland and Western Australia collect similar data. The Queensland Rheumatic Heart 
Disease Control Program register started in early 2009 but the register mainly covers North 
and Far North Queensland; therefore, most of the cases reported to the register are from the 
northern districts. Confidentialised data from the register were provided to the AIHW. The 
Western Australian Rheumatic Heart Disease Control Program register also started in early 
2009 and now covers all of Western Australia. Confidentialised summary data were 
provided to the AIHW.  
As the Northern Territory RHD register has been operating in the Top End since 1997 and in 
Central Australia since 2000, it is currently the strongest jurisdictional source of data on the 
incidence of ARF and prevalence of RHD in Australia. In contrast, the RHD register and 
control programs in Queensland and Western Australia are at different stages of 
establishment. Therefore, caution should be exercised when interpreting and comparing ARF 
incidence and RHD prevalence data across the three jurisdictions. RHD Australia has 
developed a recommended data set for ARF and RHD registers in Australia (RHD Australia 
2012). If collection of this recommended dataset is adopted, comparable data from the 
jurisdictional RHD registers may be available in the future. 
Northern Territory Rheumatic Heart Disease Control Program register 
In the Northern Territory, 317 cases of ARF were recorded on the Rheumatic Heart Disease 
Control program register between 2005 and 2010. All but six of these were in Indigenous 
people. Of the 317 cases, most (228) were new, while 76 (24% of all episodes) were recurrent. 
For the remaining 13 episodes it was unknown whether they were new or recurrent. There 
are several reasons why it might not be possible to determine whether a case of ARF is new 
or recurrent. First, if the initial episode was only diagnosed as possible ARF then a further 
episode would be difficult to define as new or recurrent and a decision may not have been 
made. Second, an episode of ARF can improve and then flare up again a few months later 
and so it may be difficult to decide whether the flare-up is a recurrence or resurgence. 
Finally, it may be due to data omission. 
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 New cases of ARF outnumber recurrent cases in all age groups (Figure 2.2). The number of 
recurrent cases among those aged under 25 suggests that the long-term prevention of ARF 
may not have been effective for a large number of people who have been treated for the 
disease. To treat ARF successfully and prevent its recurrence, antibiotics must be taken every 
4 weeks for 10 years. Such a treatment regimen relies on the provision of continuous medical 
and other locally appropriate support strategies that may not always be available in remote 
Indigenous communities. Another factor that might have an impact on effective treatment is 
a lack of adherence by the patient. Factors that could improve ongoing adherence to 
secondary prophylaxis in Australia include improving the availability of culturally 
appropriate health services for Aboriginal and Torres Strait Islander people and having a 
routine review and management plan (RHD Australia 2012).  
 
Note: Excludes cases of unknown status. 
Source: AIHW analysis of Northern Territory Rheumatic Heart Disease Control Program register data. 
Figure 2.2: Acute rheumatic fever incidence, Northern Territory, by age and episode type, 2005–2010 
In the Northern Territory between 2005 and 2010, there were 183 cases of ARF in children 
aged 5–14, accounting for 58% of all new and recurrent cases, and 76 cases in 15–24 year olds, 
accounting for a further 24% of cases (Table A1.1). Among those aged 5 and over, incidence 
rates were higher among females than males (Figure 2.3).  
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Source: AIHW analysis of Northern Territory Rheumatic Heart Disease Control Program register data. 
Figure 2.3: Acute rheumatic fever incidence rates, Northern Territory, by age and sex, 2005–2010 
Between 2005 and 2010, the age-adjusted incidence rate for ARF in the Northern Territory 
based on the registry data peaked in 2007 for both males (20.3 cases per 100,000 population) 
and females (42.3 cases per 100,000 population) (Table 2.1). Incidence rates fell between 2007 
and 2008 but have increased again since then for both sexes. Similarly to the peak in ARF 
notifications in the Northern Territory in 2007, the peak in ARF incidence rates in that year 
may be related to the temporary shortage in supply of Bicillin® L-A in that year. Dr Keith 
Edwards confirmed that another factor that might affect the identification and diagnosis of 
ARF from year to year is that there is evidence that some cases of ARF are sub-clinical as 
they present with established RHD and, if they do not score highly enough on the modified 
Jones criteria for the diagnosis of ARF, will not be diagnosed as ARF (K Edwards 2012, pers. 
comm., 5 May).  
Table 2.1: Incidence of acute rheumatic fever, Northern Territory, 2005–2010 
Sex group 2005 2006 2007 2008 2009 2010 
 Number of new and recurrent cases 
Males 16 23 26 14 21 23 
Females 26 26 50 28 31 33 
Persons 42 49 76 42 52 56 
 Number of cases per 100,000 population(a) 
Males 12.7 18.7 20.3 10.6 15.9 17.6 
Females 22.7 23.3 42.3 23.1 25.3 27.6 
Persons 17.5 20.9 31.0 16.7 20.5 22.4 
(a) Age-standardised to the 2001 Australian population. 
Source: AIHW analysis of Northern Territory Rheumatic Heart Disease Control Program register data. 
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 Queensland Rheumatic Heart Disease Control Program register 
As at 27 August 2012, there were 1,385 patients registered on the Queensland Rheumatic 
Heart Disease register.  
There were 200 ARF notifications in the 3 years from 2009 to 2011, but 22 of these cases were 
subsequently ruled out, leaving a total of 178. Of these 178 notifications, 61% were new cases, 
10% were recurrent, and for the remaining 29% it was not known whether they were new or 
recurrent. The majority (90%) of cases of ARF occurred in Indigenous people. Just over 60% 
of cases occurred in 5–14 year olds and another 19% in 15–19 year olds. In contrast to the 
picture in the Northern Territory, there was no gender differential in the incidence of ARF in 
Queensland, with half of the cases occurring in females and half in males (49% versus 51%). 
Western Australian Rheumatic Heart Disease Control program register 
Between 1 July 2010 and 30 June 2011, there were 21 new and recurrent cases of ARF notified 
to the newly established Western Australia Rheumatic Heart Disease register (Table 2.2). All 
21 cases occurred in Aboriginal and Torres Strait Islander people, with 57% in males (12 
cases). 
Table 2.2: New and recurrent cases of acute rheumatic fever, Western Australia, 2010–11 
Age group (years) Males Females Persons 
  Number of cases  
0–14 7 5 12 
15+ 5 4 9 
Total 12 9 21 
Source: Western Australia Rheumatic Heart Disease Control Program register. 
2.2 Deaths 
Between 2007 and 2009, there were 12 deaths in Australia where ARF was the underlying 
(main) cause of death. This suggests that it is uncommon for ARF to be recorded as the 
underlying cause of death.  
The small number of deaths from ARF also means that it is difficult to confidently determine 
the proportion of ARF deaths that occur among Indigenous Australians. Further, the latest 
year for which unit record mortality data by Indigenous status were available for analysis for 
this report was 2007. Between 2004 and 2007, 13 deaths with an underlying cause of death of 
ARF were recorded among the jurisdictions for which Indigenous identification was 
considered reliable for mortality data (New South Wales, Queensland, Western Australia, 
South Australia and the Northern Territory), and less than one-third of these deaths occurred 
in people who identified as being of Aboriginal and Torres Strait Islander origin. 
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 3 Rheumatic heart disease 
3.1 Prevalence 
It is not possible to give a complete picture of RHD in Australia as no national prevalence 
data exist. However, jurisdictional data are available from the Northern Territory, 
Queensland and Western Australian RHD registers. 
Northern Territory 
As at 31 December 2010, there were 1,479 cases of RHD in the Northern Territory—969 cases 
in females and 510 in males. RHD prevalence rates were lowest among 0–14 year olds. 
Among those aged 15 and over, the prevalence of RHD was higher among 15–44 year old 
females than among females aged 45 year and over, while prevalence rates in males declined 
between the ages of 15 and 64 before increasing slightly again in those aged 65 and over 
(Figure 3.1). Prevalence rates were higher among females than males in all age groups.  
 
Note: Age-specific rates calculated using the 2010 estimated resident population for the Northern Territory. 
Source: AIHW analysis of Northern Territory Rheumatic Heart Disease Control Program register data. 
Figure 3.1: Rheumatic heart disease prevalence rates in the Northern Territory, by age and sex, 2010 
The prevalence of RHD in the Northern Territory appears to be increasing. Between 2004 and 
2010, the age-standardised prevalence rate increased from 555 cases per 100,000 population 
to 647, an increase of 17%. The biggest increase occurred in persons aged 65 and over, for 
whom the rate increased by 50% from 433 cases per 100,000 population in 2004 to 650 cases 
per 100,000 in 2010 (Table A2.1). This increase in older persons may be due to the ongoing 
ascertainment of existing cases rather than development of new disease. Over the 7 years, 
females had consistently higher rates than males (Figure 3.2). It is possible that this increase 
is the result of improved diagnosis and data collection rather than a true increase in the 
prevalence of the disease. 
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Note: Age-standardised to the 2001 Australian population. 
Source: AIHW analysis of Northern Territory Rheumatic Heart Disease Control Program register data. 
Figure 3.2: Prevalence of rheumatic heart disease in the Northern Territory, by sex, 2004 to 2010 
In 2010, RHD was much more prevalent among Indigenous people in the Northern Territory 
(1,379 cases) than it was among non-Indigenous Australians (100 cases). After adjusting for 
the different age structures of the populations, the prevalence rate among Indigenous 
Australians was 26 times as high as for non-Indigenous Australians —2,474 per 100,000 
population (that is, 2.5% of the total Indigenous population in the Northern Territory) 
compared with 94 cases per 100,000 population (that is, 0.1% of the total non-Indigenous 
population in the Northern Territory). 
Among Indigenous Australians in the Northern Territory, RHD prevalence rates were high 
across all age groups, with the highest among those aged 35–64 (Figure 3.3). In contrast, 
prevalence rates among non-Indigenous Australians increased steadily with age, with the 
highest in those aged 65 and over.  
The most marked difference between Indigenous and non-Indigenous Australians in the 
prevalence of RHD occurred in those aged under 35, where Indigenous Australians had a 
122–fold greater prevalence than non-Indigenous Australians. This suggests that RHD is rare 
in young non-Indigenous Australians in the Northern Territory. While the differential 
between Indigenous and non-Indigenous Australians fell with increasing age, Indigenous 
Australians aged 65 and over in the Northern Territory still had a prevalence rate of RHD 
that was 6 times as high as that of their non-Indigenous counterparts. The shorter life 
expectancy of Indigenous Australians may also account for some of these changes in ratio. 
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Note: Age-specific rates calculated using the 2006 estimated resident Indigenous and non-Indigenous populations for the Northern Territory. 
Source: AIHW analysis of Northern Territory Rheumatic Heart Disease Control Program register data. 
Figure 3.3: Rheumatic heart disease prevalence rates in the Northern Territory, by age and 
Indigenous status, 2010 
Queensland 
Of the 1,385 patients registered on the Queensland Rheumatic Heart Disease Control 
Program register as at 27 August 2012, there were 939 patients who had progressed to RHD, 
166 patients who did not have RHD and 280 cases yet to be reviewed or whose RHD status 
was unknown.  
Of the 939 patients with RHD, 90% were Aboriginal or Torres Strait Islander people, 9% were 
not Indigenous and 1% were of unknown Indigenous status. Almost two-thirds of those with 
RHD were female (596 cases) but most of these cases occurred in females who were aged 25 
years and over (66%) (Figure 3.4). In contrast, the majority of cases of RHD in males (55%) 
occurred in those aged under 25.  
Western Australia 
As at 30 June 2011, there were 158 patients with confirmed RHD registered on the Western 
Australia Rheumatic Heart Disease register. Of these RHD patients, all were Aboriginal and 
Torres Strait Islander people and the majority (61%) were female (97 cases). Just over two-
fifths (42%) of those with RHD were aged 0–24 (67 cases), while 36% were aged 25–44 (57 
cases) and 22% were aged 45 and over (34 cases). 
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Source: AIHW analysis of Queensland Rheumatic Heart Disease Control Program register data. 
Figure 3.4: Number of cases of rheumatic heart disease in Queensland, by sex and age as at  
27 August 2012 
3.2 Deaths 
Between 2007 and 2009, there were 897 deaths recorded nationally with RHD as the 
underlying cause of death. This equates to 0.6% of all cardiovascular disease (CVD) deaths 
(141,819) and 0.2% of all deaths (422,560) over this period. The average death rate over the  
3 years was 1.4 per 100,000 population (Table A2.2).  
Sex and age 
Unlike other forms of CVD, more females die from RHD than males. Between 2007 and 2009, 
females accounted for more than two-thirds of RHD deaths—606 compared with 291 for 
males. The age-adjusted death rate for females (1.5 per 100,000 population) was 50% higher 
than the male rate (1.0 per 100,000) (Table A2.2; Figure 3.5). The higher RHD death rate in 
females compared with males is consistent with the higher RHD prevalence and 
hospitalisation rates in females. 
Death rates increased rapidly with age, with the greatest rates among those aged 85 and over 
(Figure 3.5). More than 80% of deaths occurred among people aged 65 and over. 
In contrast to ARF, RHD predominately affects older Australians, with more than 80% of 
deaths occurring in those aged 65 and over. Consistent with the hospitalisation rates for 
RHD, death rates are higher among older Australians.  
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Note: Cause of death data for 2009 are preliminary and are subject to further revision. 
Source: Analysis of the AIHW National Mortality Database.  
Figure 3.5: Rheumatic heart disease death rates, underlying cause, by age and sex, 2007–2009 
Aboriginal and Torres Strait Islander people  
Between 2004 and 2007, there were 63 deaths from RHD among Indigenous Australians 
(Table A2.3). The age-standardised death rate for Indigenous Australians (5.8 per 100,000 
population) was 5.2 times as high as the rate for non-Indigenous Australians (1.1 per 100,000 
population). Across all age groups, Indigenous Australians consistently had higher death 
rates than non-Indigenous Australians (Figure 3.6). However, it is interesting to note that the 
magnitude of the difference is lower in those aged 65 and over.  
State and territory 
Between 2005 and 2007, the Northern Territory had the highest age-standardised RHD death 
rate (5.8 per 100,000 population) of any state or territory (Table A2.4; Figure 3.7). This rate 
was 4.7 times as high as the national average. Among the other jurisdictions, there was not a 
great deal of variation in the RHD death rates over the 3 years, with the age-adjusted rates 
ranging from 1.1 per 100,000 population in New South Wales and the Australian Capital 
Territory to 1.8 per 100,000 in Tasmania.  
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Note: Data from NSW, QLD, WA, SA, NT only. 
Source: Analysis of the AIHW National Mortality Database. 
Figure 3.6: Rheumatic heart disease death rates, underlying cause, by Indigenous status and  
age, 2004–2007 
 
 
Note: Age-standardised to the Australian population as at 30 June 2001.  
Source: Analysis of the AIHW National Mortality Database. 
Figure 3.7: Rheumatic heart disease death rates, underlying cause, by state and territory of 
residence, 2005–2007 
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 Trends  
Between 1979 and 1996, death rates for RHD in Australia more than halved, falling from 2.0 
to 0.9 deaths per 100,000 population for males and 3.1 to 1.1 deaths per 100,000 population 
for females (Table A2.5; Figure 3.8). Death rates increased again between 1996 and 1997 by an 
average of 0.8 deaths per 100,000 population, but have stabilised since 1998. Over the 31 
years to 2009, the age-standardised death rates were consistently higher for females than 
males, reflecting the higher prevalence of rheumatic heart disease in females. 
 
Notes 
1.  Age-standardised to the Australian population as at 30 June 2001. 
2.  Death rates for 1979–1996 have been adjusted to ICD-10 standards using a comparability factor of 0.69. 
3. Cause of death data for 2009 are preliminary and are subject to further revision. 
Source: Analysis of the AIHW National Mortality Database.  
Figure 3.8 Rheumatic heart disease death rates, underlying cause, by sex, 1979–2009 
Contribution of other cardiovascular diseases, chronic kidney 
disease and diabetes to deaths involving RHD 
In addition to the 897 deaths registered between 2007 and 2009 where RHD was the 
underlying cause of death, there were another 1,185 deaths where RHD was recorded as an 
associated cause of death. An associated cause of death is a disease or condition, other than 
the underlying cause, that was instrumental in causing death (AIHW 2012). 
It is common for people who die with RHD to have another CVD listed on the death 
certificate as having contributed to the death. Of the 2,082 deaths registered between 2007 
and 2009 that involved RHD, 90% had at least one other CVD listed as a cause of death 
(Table 3.1). Chronic kidney disease (CKD) was listed as contributing to the death for 19% of 
deaths involving RHD, while diabetes was listed for 11% of deaths involving RHD. Only 7% 
of deaths involving RHD did not have another CVD, CKD or diabetes contributing to the 
death. This suggests that it is not only the RHD that adversely affects health, but also its 
interaction with other vascular diseases.  
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 Table 3.1: Contribution of other cardiovascular diseases, chronic kidney disease and diabetes to 
deaths where RHD was the underlying or an associated cause of death, 2007–2009 
Causes of death Number of deaths Per cent 
RHD (without other CVDs, diabetes or CKD) 151 7.3 
RHD and CKD (without diabetes or other CVDs) 32 1.5 
RHD and diabetes (without other CVDs or CKD) 11 0.5 
RHD and other CVDs (without diabetes and CKD) 1,371 65.9 
RHD, diabetes and CKD (without other CVDs) 6 0.3 
RHD, other CVDs and CKD (without diabetes) 291 14.0 
RHD, other CVDs and diabetes (without CKD) 155 7.4 
RHD, other CVDs, diabetes and CKD 65 3.1 
Total deaths where RHD was the underlying or an associated cause 
of death 2,082 100.0 
Note: Cause of death data for 2009 are preliminary and are subject to further revision. 
Source: AIHW National Mortality Database. 
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 4 Hospitalisations for acute rheumatic 
fever and rheumatic heart disease 
In this chapter ARF and RHD have been grouped together because age patterns for 
hospitalisations where ARF was the principal diagnosis suggest that hospital records may 
not always accurately distinguish between ARF and RHD. In 2009–10, there were 2,666 
hospitalisations with a principal diagnosis of ARF or RHD in Australia—0.6% of all 
cardiovascular disease hospitalisations (482,252 hospitalisations). This equates to a crude rate 
of 12 hospitalisations per 100,000 population (Table A3.1). The principal diagnosis is the 
diagnosis established to be the problem that was chiefly responsible for the patient‘s episode 
of care in hospital (AIHW 2011a). 
Sex and age 
With the exception of 15–19 year olds, females had higher rates of hospitalisation with ARF 
or RHD than males in 2009–10 (Figure 4.1). Overall, the age-standardised hospitalisation rate 
for females (13 per 100,000 population) was 1.3 times as high as that for males (10 per 
100,000).  
 
Note: Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart disease; excludes hospitalisations for unqualified 
neonates, boarders and organ procurement. 
Source: AIHW National Hospital Morbidity Database. 
Figure 4.1: Rates for hospitalisations with a principal diagnosis of acute rheumatic fever or 
rheumatic heart disease, by sex and age, 2009–10 
Hospitalisation rates increased sharply with age between the ages of 55 and 84, with the rate 
among 65–74 year olds being 2.5 times as high as that among 55–64 year olds. The highest 
rates were in those aged 75–84 years—59 hospitalisations per 100,000 population for males 
and 63 per 100,000 for females (Table A3.1). Among children aged 0–14, the increase in 
hospitalisation rates for ARF or RHD with age is likely to be due to exposure to ARF. 
However, among people aged 15 and over, the increase in hospitalisation rates from the age 
of 55 is likely to be due to RHD and its treatment. 
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 Aboriginal and Torres Strait Islander people 
Between 2007–08 and 2009-10, in jurisdictions with adequate Indigenous identification, there 
were 1,065 hospitalisations with a principal diagnosis of ARF or RHD for Aboriginal and 
Torres Strait Islander people and 6,519 hospitalisations for other Australians (Table A3.2).  
After adjusting for age, the overall rate of hospitalisation with ARF or RHD for Indigenous 
Australians (67 per 100,000 population) was 6.7 times as high as that of other Australians (10 
per 100,000). Aboriginal and Torres Strait Islander people had higher age-specific rates than 
other Australians in all age groups, although the rates for the two groups were closer for the 
65 and over age group (Figure 4.2).  
 
Notes   
1.  Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart disease; excludes hospitalisations for unqualified 
neonates, boarders and organ procurement. 
2.  Based on patients usually resident in New South Wales, Victoria, Queensland, Western Australia, South Australia and the Northern 
Territory; excludes private hospitals in the NT. 
3.  Other Australians include peoples whose Indigenous status was ‘Not stated’. 
Source: AIHW Hospital Morbidity Database. 
Figure 4.2: Rates for hospitalisations with a principal diagnosis of acute rheumatic fever or 
rheumatic heart disease, by Indigenous status and age, 2007–08 to 2009–10 
State and territory  
In 2009–10, the Northern Territory had the highest age-adjusted rate of hospitalisations with 
a principal diagnosis of ARF or RHD (86 hospitalisations per 100,000 population) (Table 
A3.3). This was followed by Queensland (15 hospitalisations per 100,000 population) and 
Western Australia (12 hospitalisations per 100,000 population).  
Among people aged under 65, the Northern Territory had a much greater rate of 
hospitalisations for ARF or RHD than any other jurisdiction in 2009–10 (Figure 4.3). 
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Notes  
1.  Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart disease; excludes hospitalisations for unqualified 
neonates, boarders and organ procurement. 
2.  Age-standardised to the 2001 Australian population. 
Source: AIHW National Hospital Morbidity Database. 
Figure 4.3: Rates for hospitalisations with a principal diagnosis of acute rheumatic fever or 
rheumatic heart disease, by age and state and territory of residence, 2009–10 
Trends  
Between 1999–00 and 2009–10, the number of hospitalisations with a principal diagnosis of 
ARF or RHD increased from 2,191 to 2,666. Overall, there was little change in the age-
standardised hospitalisation rate over this period. However, for males the rate increased 
slightly between 1999–00 and 2007–08, from 9.3 to 11.3 hospitalisations per 100,000 
population, but has since fallen (Table A3.4). Females had consistently higher hospitalisation 
rates than males over the 11 years (Figure 4.4). The pattern of higher hospitalisation rates in 
females is consistent with the higher ARF incidence and RHD prevalence rates in females 
from the Northern Territory Rheumatic Heart Disease Control Program register. Also, as 
mentioned earlier, the gender difference might be the result of higher use and exposure to 
health services by the female population, but to date no evidence can substantiate these 
results. 
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Notes  
1.  Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart disease; excludes hospitalisations for unqualified 
neonates, boarders and organ procurement. 
2.  Age-standardised to the 2001 Australian population. 
Source: AIHW National Hospital Morbidity Database. 
Figure 4.4: Rates for hospitalisations with a principal diagnosis of acute rheumatic fever or 
rheumatic heart disease, by sex, 1999–00 to 2009–10 
Contribution of other cardiovascular diseases, chronic kidney 
disease and diabetes to hospitalisations involving ARF or RHD 
In addition to the 2,666 hospitalisations with a principal diagnosis of ARF or RHD in 2009–
10, there were another 8,581 hospitalisations with an additional diagnosis of ARF and/or 
RHD. The additional diagnosis is a condition or complaint either coexisting with the 
principal diagnosis or arising during the episode of care (AIHW 2011a). 
It is common for people hospitalised with ARF or RHD to have a principal or additional 
diagnosis of another CVD associated with the hospitalisation. In 2009–10, 84% of the 11,247 
hospitalisations with any diagnosis of ARF or RHD also had a diagnosis of another CVD 
(Table 4.1). Almost one-fifth (18%) of hospitalisations involving ARF or RHD also had 
another diagnosis of CKD, while 15% had a diagnosis of diabetes. Only 15% of 
hospitalisations involving ARF or RHD did not have a diagnosis of another CVD, CKD or 
diabetes recorded. 
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 Table 4.1: Contribution of other cardiovascular diseases, chronic kidney disease and diabetes 
contributing to hospitalisations with a principal or an additional diagnosis of acute rheumatic 
fever or rheumatic heart disease, 2009–10 
Diagnosis Number of hospitalisations Per cent 
ARF or RHD (without other CVDs, diabetes or CKD) 1,659 14.8 
ARF or RHD and CKD (without diabetes or other CVDs) 46 0.4 
ARF or RHD and diabetes (without other CVDs or CKD) 41 0.4 
ARF or RHD and other CVDs (without diabetes and CKD) 6,644 59.1 
ARF or RHD, diabetes and CKD (without other CVDs)  19 0.2 
ARF or RHD, other CVDs and CKD (without diabetes)  1,156 10.3 
ARF or RHD, other CVDs and diabetes (without CKD) 829 7.4 
ARF or RHD, other CVDs, diabetes and CKD  853 7.6 
Total hospitalisations with a principal or additional diagnosis of 
ARF or RHD  11,247 100.0 
Source: AIHW National Hospital Morbidity Database. 
Heart valve surgery for RHD 
Valve surgery and interventional cardiology such as balloon valvuloplasty are the most 
common types of therapeutic procedures performed in hospital for people with RHD. 
Whether or not such interventions are required for an individual with RHD depends on the 
presence of symptoms and the severity of the heart valve damage and, if an intervention is 
indicated, the type performed depends on the type of heart valve damage.  
Note that all heart valve procedures reported here relate to hospitalisations with a principal 
diagnosis of ARF or RHD among people aged 15 and over. While it would be rare for a 
person with ARF to have heart valve surgery, hospitalisations with a principal diagnosis of 
ARF have been included with those for RHD to ensure that any conflation of RHD as ARF is 
accounted for. 
In 2009-10, there were 2,449 hospitalisations with a principal diagnosis of ARF or RHD 
among people aged 15 and over and, of these hospitalisations, 49% had at least one heart 
valve procedure performed (Table 4.2). Replacement of the mitral and aortic valves were the 
most common heart valve procedures performed for these hospitalisations, accounting for 
23% and 22% respectively.  
  
 Rheumatic heart disease and acute rheumatic fever in Australia: 1996–2012 23 
 Table 4.2: Heart valve procedures performed for hospitalisations with a principal diagnosis of 
acute rheumatic fever or rheumatic heart disease among people aged 15 and over, 2009–10 
Heart valve procedures 
Number of heart 
valve 
procedures 
Per cent of all heart 
valve procedures 
Number of 
hospitalisations with a 
principal diagnosis of 
ARF or RHD that had at 
least one heart valve 
procedure performed(a) 
Per cent of all 
hospitalisations with a 
principal diagnosis of 
ARF or RHD (n=2,449) 
Replacement of mitral 
valve 581 28.8 581 23.7 
Replacement of aortic 
valve 562 27.8 558 22.8 
Tricuspid valve 
annuloplasty 256 12.7 256 10.5 
Repair of mitral valve 236 11.7 229 9.4 
Mitral valve annuloplasty 212 10.5 211 8.6 
Other heart valve 
procedures(b) 173 8.6 166 6.8 
All heart valve 
procedures 2,020 100.0 1,208 49.3 
(a) Components do not add to total because a patient may have had more than one type of heart valve procedure. 
(b) Includes repair, replacement, incision and other procedures on the pulmonary valve; repair, replacement, incision and other procedures on 
the tricuspid valve; reconstruction, incision and other procedures on the mitral valve; repair, incision and other procedures on the aortic 
valve. 
Source: AIHW National Hospital Morbidity Database. 
Aboriginal and Torres Strait Islander people  
Aboriginal and Torres Strait Islander people are more likely to be hospitalised than other 
Australians, however, they are less likely to undergo a procedure once admitted to hospital 
(AIHW 2011a). The results of multivariate analysis reported in Aboriginal and Torres Strait 
Islander Health Performance Framework 2010: detailed analyses (AIHW 2011a) showed that for 
both Indigenous and other Australians some of the most important factors contributing to 
whether a patient received a procedure related to their principal diagnosis once hospitalised 
were: the number of additional diagnoses, the hospital sector (that is, public or private), the 
principal diagnosis, remoteness of usual residence, state of usual residence, age and sex. 
After controlling for these variables, the odds of receiving a procedure for Indigenous 
Australians was about 40% less than the odds for other Australians. 
Between 2007–08 and 2009–10, there were 675 hospitalisations with a principal diagnosis of 
ARF or RHD among Indigenous Australians aged 15 and over and 6,348 among other 
Australians of the same age. After adjusting for age, the rate of these hospitalisations in 
Aboriginal and Torres Strait Islander people (65.9 per 100,000 population) was 5.4 times as 
high as the corresponding rate in other Australians (12.2 per 100,000 population). However, 
over the 3 years, Indigenous Australians were less likely than other Australians to have had 
at least one heart valve procedure performed when hospitalised with a principal diagnosis of 
ARF or RHD (28% compared with 49%) (Table 4.3). 
Replacement of the mitral valve was the most common heart valve procedure for Aboriginal 
and Torres Strait Islander people aged 15 and over (15% of hospitalisations with a principal 
diagnosis of ARF or RHD) (Table 4.3). This was also a common procedure among other 
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 Australians aged 15 and over (23% of hospitalisations with a principal diagnosis of ARF or 
RHD) as was replacement of the aortic valve (23%).  
Table 4.3: Heart valve procedures performed for hospitalisations(a) with a principal diagnosis of 
acute rheumatic fever or rheumatic heart disease among people aged 15 and over, by Indigenous 
status, 2007–08 to 2009–10 
 
Number of hospitalisations 
with a principal diagnosis of 
ARF or RHD that had at least 
one heart valve procedure 
performed 
Per cent of all hospitalisations with a 
principal diagnosis of ARF or RHD 
Heart valve procedures  
Indigenous 
Australians(a) 
Other 
Australians(b) 
Indigenous 
Australians  
 (N =675) 
Other Australians 
(N= 6,348) 
Replacement of mitral valve 100 1,450 14.8 22.8 
Replacement of aortic valve 50 1,437 7.4 22.6 
Tricuspid valve annuloplasty 46 732 6.8 11.5 
Repair of mitral valve 37 614 5.5 9.7 
Mitral valve annuloplasty 30 588 4.4 9.3 
Other heart valve procedures(c) 23 417 3.4 6.6 
All heart valve procedures(d) 188 3,096 27.9 48.8 
(a) Based on patients usually resident in New South Wales, Victoria, Queensland, Western Australia, South Australia and the  
Northern Territory; excludes private hospitals in the NT. 
(b) Other Australians include peoples whose Indigenous status was ‘Not stated’. 
(c) Includes repair, replacement, incision and other procedures on the pulmonary valve; repair, replacement, incision and other  
procedures on the tricuspid valve; reconstruction, incision and other procedures on the mitral valve; repair, incision and other  
procedures on the aortic valve. 
(d) Components do not add to total because a patient may have had more than one type of heart valve procedure. 
Source: AIHW National Hospital Morbidity Database. 
For both Indigenous and other Australians, the proportion of hospitalisations between  
2007–08 and 2009–10 with a principal diagnosis of ARF or RHD that had at least one heart 
valve procedure was higher among those aged 55 and over than those aged 15–54 (Table 4.4). 
Just over one-quarter (26%) of these hospitalisations among Aboriginal and Torres Strait 
Islander people aged 15–54 had at least one heart valve procedure performed, compared 
with 41% among those aged 55 and over. For other Australians, the proportion that had a 
heart valve procedure was 44% for those aged 15–54 and 50% for those aged 55 and over. 
Thus, in both age groups, hospitalisations for ARF or RHD among Aboriginal and Torres 
Strait Islander people were less likely to have had a heart valve procedure recorded than 
other Australians. 
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 Table 4.4: Proportion of hospitalisations(a) with a principal diagnosis of acute rheumatic fever or 
rheumatic heart disease among people aged 15 and over that had at least one heart valve procedure 
performed, by Indigenous status, 2007–08 to 2009–10 
 
Hospitalisations with a 
principal diagnosis of ARF 
or RHD  
Number of hospitalisations 
with a principal diagnosis of 
ARF or RHD that had at least 
one heart valve procedure 
performed  
Per cent of all hospitalisations 
with a principal diagnosis of ARF 
or RHD 
Age group 
(years) 
Indigenous 
Australians 
Other 
Australians(b) 
 Indigenous 
Australians 
Other 
Australians(b) 
 Indigenous 
Australians 
Other 
Australians(b) 
15–54 604 1,167  159 518  26.3 44.4 
55+ 71 5,181  29 2,578  40.8 49.8 
All ages 675 6,348  188 3,096  27.9 48.8 
(a) Based on patients usually resident in New South Wales, Victoria, Queensland, Western Australia, South Australia and the Northern 
Territory; excludes private hospitals in the NT. 
(b) Other Australians include peoples whose Indigenous status was ‘Not stated’ 
Source: AIHW National Hospital Morbidity Database. 
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 5 Adherence to secondary prophylaxis in 
the Northern Territory 
People who develop ARF are at a relatively high risk of developing recurrent episodes and, 
to prevent recurrences, should be treated with antibiotics after their first attack. The current 
Australian guidelines state that secondary prophylaxis with benzathine penicillin G (BPG) 
injections is recommended in all people with a history of ARF or RHD (RHD Australia 2012). 
For patients not considered to be at high risk, the current treatment of choice is 4-weekly 
BPG injections. However, 3-weekly BPG administration is recommended for patients 
considered to be at high risk. The guideline also states that all people with ARF or RHD 
should continue secondary prophylaxis for at least 10 years after the last episode of ARF or 
until the age of 21, whichever is the longer. People with mild RHD who have completed 10 
years of secondary prophylaxis do not need to continue treatment after that time. People 
with moderate RHD should continue secondary prophylaxis until the age of 35, while those 
with severe RHD should continue treatment until the age of 40, or longer if they wish.  
The length of time over which secondary prophylaxis needs to be administered is a major 
challenge in ensuring compliance with the recommended protocol (that is, adherence) 
particularly for Aboriginal and Torres Strait Islander people (Parnaby & Carapetis 2010). 
Other factors that affect adherence with secondary prophylaxis in remote Australian 
Aboriginal and Torres Strait Islander communities are the availability and acceptability of 
health services. A study from the Northern Territory has shown that patients had better 
adherence to treatment when they felt that their care was more personalised and that they 
had a sense of belonging to the clinic (Harrington et al. 2006). Other studies have also shown 
that adherence to secondary prophylaxis was improved by active follow-up of patients who 
missed an injection and where monthly injections were given by a dedicated staff member 
(RHD Australia 2012). RHD control programs are the most effective way of improving 
adherence to secondary prophylaxis of ARF and clinical follow-up of people with RHD 
(RHD Australia 2012). For this reason, the RHD control programs are a key focus of the 
Government’s Rheumatic Fever Strategy. 
The number of people registered for secondary prophylaxis in the Northern Territory 
increased from 758 in 2005 to 1,116 in 2010 (Table 5.1). One factor that is likely to have 
contributed to this increase is the introduction, in 2007, of an automated process for 
identifying and reporting back to health centres those patients requiring secondary 
prophylaxis (Parnaby 2011). 
Of the 5,816 patients receiving treatment over the 6 years, 57% (3,340) had a diagnosis of 
RHD, 35% (2,052) had a diagnosis of ARF and the rest (7%, or 424) had a diagnosis of either 
possible ARF or possible RHD. Note that not all people with RHD who are registered on the 
Northern Territory RHD register will also be registered for secondary prophylaxis as 
prophylactic treatment ceases after a period of time depending on the severity of the RHD.  
The proportion of patients receiving more than 80% of their required doses has improved 
over time from 23% in 2005 to 28% in 2010, though still remains quite low. Since 2007, there 
has also been an increase in the proportion of patients receiving 50–80% of required doses 
and a decrease in the proportion receiving less than 50% (Table 5.1). 
A contributing factor to this increase is the development of automated master charts that are 
sent through to health centres. In the past, staff at health centres were required to identify 
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 patients for secondary prophylaxis. The automated master charts have taken over this task of 
going through individual charts to identify patients and this has reduced the likelihood of 
patients ‘falling through the cracks’. 
Table 5.1: Adherence to secondary prophylaxis in the last 12 months for persons registered on the 
Northern Territory ARF/RHD Control Program, 2005–2010 
 Treatment year    
Percentage of required doses 
received in the previous 12 months 2005 2006 2007 2008 2009 2010 2005–2010 
 Number of people 
< 50% 303 380 417 399 365 337 2,201 
50-80% 283 319 329 364 439 465 2,199 
> 80%(b) 172 203 230 231 266 314 1,416 
Total people registered 758 902 976 994 1,070 1,116 5,816 
 Coverage (per cent) 
< 50% 40.0 42.1 42.7 40.1 34.1 30.2 37.8 
50-80% 37.3 35.4 33.7 36.6 41.0 41.7 37.8 
> 80%(a) 22.7 22.5 23.6 23.2 24.9 28.1 24.3 
(a) Includes people who received one or more doses when none were required. 
Source: AIHW analysis of Northern Territory Rheumatic Heart Disease Program data. 
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 6 Expenditure on acute rheumatic fever 
and rheumatic heart disease 
This chapter presents the most recent (2008–09) health-care expenditure estimates for ARF 
and RHD in Australia. The estimates include expenditure by the Australian Government, 
state, territory and local governments and the non-government sector (such as private health 
insurance and individual contributions).  
Estimates are sourced from the AIHW Disease Expenditure Database (see Appendix B). 
Health expenditure comprises recurrent and capital spending on hospital services, medical 
services, dental services, other health practitioner services, patient transport services, 
medicines, community and public health services, aids and appliances, health administration 
and health research.  
It is important to note that only estimates of direct health expenditure are included in this 
report. Direct health expenditure relates to preventing, diagnosing and treating health 
problems. These estimates do not include costs that are not accrued by the health system, 
such as travel costs of patients, costs associated with the social and economic burden on 
carers and family, and costs relating to lost quality and quantity of life. Therefore, the 
estimates reported here do not represent the total economic impact of ARF and RHD in the 
Australian community.  
It is not possible to allocate all expenditure on health goods and services by disease. 
Expenditure on most community and public health programs, for instance, support the 
treatment and prevention of many conditions and cannot be allocated to one specific disease 
or injury. This is also true of capital expenditure on health facilities and equipment, which 
has the added problem of being characterised by large outlays that fluctuate greatly from 
year to year. For 2008–09, the areas of health expenditure that could not be allocated by 
disease were: 
• hospital non-admitted patient services 
• over-the counter medications 
• other health practitioner services (apart from optometry) 
• community health programs (apart from community mental health) 
• public health (apart from cancer screening programs) 
• health administration 
• patient transport services 
• health aids and appliances  
• health research 
• capital expenditure. 
How much is spent on ARF and RHD? 
In 2008-09, about $74 million (0.1%) of the $74.2 billion health expenditure that could be 
allocated by disease was spent on ARF and RHD, equating to just 1% of all CVD health 
expenditure. Expenditure per person for ARF and RHD was highest among people aged 75–
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 84 years ($20.10 per person in the Australian population). Among 5–34 year olds, 
expenditure for ARF and RHD was $0.73 per person, while for those aged 35–74 it ranged 
from $1.33 to $12.72 per person. The per person expenditure was higher for females than 
males between 15 to 74 but the opposite was true for the 75 to 84 year age group where males 
had higher expenditures than females ($20.60 compared with $19.71 per person) (Figure 6.1). 
 
Source: AIHW Disease Expenditure Database. 
Figure 6.1: Health care expenditure ($) for ARF and RHD per person, by age and sex, 2008–09 
In 2008-09, estimated expenditure on admitted patients ($73.5 million) accounted for 98.8% 
of the total expenditure that could be allocated to ARF and RHD. Of the remaining 
expenditure on ARF and RHD in 2008–09, $553,600 (0.7%) was spent on 
out-of-hospital medical services, and $365,300 (0.5%) on prescription pharmaceuticals. 
Aboriginal and Torres Strait Islander people 
In 2008–09, expenditure on hospitalisations for Aboriginal and Torres Strait Islander people 
with ARF or RHD was $5.9 million, which accounted for 0.4% of all admitted patient 
expenditure for Aboriginal and Torres Strait Islander people ($1,470.5 million) (AIHW 
2011b). Hospital expenditure per person for ARF and RHD for Aboriginal and Torres Strait 
Islander people was 4.3 times as high as that for non-Indigenous Australians ($10.9 
compared with $2.5). However, this only reflects the cost of in-hospital care, while a great 
part of the care including prophylaxis is supplied by community health-care centres. 
However, it should be noted that these estimates were modelled using Indigenous  
under-identification factors. As some of the expenditure patterns may be influenced by 
variations in the completeness of Indigenous identification, it is possible that health 
expenditure estimates for Indigenous Australians may slightly overestimate or 
underestimate the actual level of health expenditure. As a result, these estimates should be 
interpreted with caution. 
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 7 International comparisons 
7.1 Incidence of ARF 
International comparisons of ARF incidence are difficult to make and for many regions 
(including China and sub-Saharan Africa) no studies are available. Based on studies from 
countries for which data were available, it has been estimated that at least 471,000 new cases 
of ARF occur each year, with 95% of those coming from low- to middle-income countries 
(Carapetis et al. 2005b; World Health Organization 2005).  
Based on studies conducted between the late 1970s and 2002, the highest ARF incidence rates 
among children and adolescents were in the Pacific Island and Indigenous Australian and 
New Zealand populations. Incidence rates in this group ranged from 40 to 815 per 100,000 
population, with a median incidence of 374 cases per 100,000 (WHO 2005). By comparison, 
the lowest incidence rates—about 10 cases per 100,000 population—were observed in studies 
conducted in New Zealanders of European descent and in Hawaii (WHO).  
Authors of a more recent international review confirm the high incidence of ARF in the 
Western Pacific region, which includes Australia (Seckeler & Hoke 2011). These authors 
compared the reported incidence of ARF in WHO regions worldwide and found that it was 
decreasing in all regions except the Americas and the Western Pacific. Improved living 
conditions and antibiotic treatment for GAS infection are believed to have contributed to the 
decreasing trend in ARF incidence in most regions of the world. The increase in ARF 
incidence in the Western Pacific is thought to be due to improved recognition and reporting 
of ARF in this region since the early 1990s.  
How does the incidence of ARF in the Northern Territory compare? 
Data from the Northern Territory RHD register presented in this report, and elsewhere, 
show that the incidence of ARF in the Northern Territory, particularly among Aboriginal and 
Torres Strait Islander children, is much higher than that reported for other developed 
countries. Between 2005 and 2010, the incidence rate in the Northern Territory was about 110 
per 100,000 population for girls aged 5–14 and 70 per 100,000 for boys of the same age 
(Figure 2.3). For Aboriginal and Torres Strait Islander children aged 5–14 in the Northern 
Territory, Parnaby & Carapetis (2010) estimated that the incidence of ARF between 2002 and 
2008 ranged from 150 to 380 per 100,000 population.  
7.2 Prevalence of RHD 
In their review of the global burden of group A streptococcal diseases, Carapetis et al. 
(2005b) estimated that globally there were at least 15.6 million people with RHD and that 
60% of all cases of ARF would develop RHD each year. 
The review of published evidence by Seckeler and Hoke (2011) found that the prevalence of 
RHD had been increasing in the major regions (Africa, South East Asia, Americas, Eastern 
Mediterranean and Western Pacific) of the world except Europe, despite a continuous 
decrease in the incidence of ARF between 1970 and 2009 in most of these regions. Improved 
diagnosis and an increase in survival of people with RHD are believed to contribute to this 
worldwide trend.  
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 Internationally among children aged 5–14, Carapetis et al. (2005b) found that the prevalence 
of RHD between 1985 and the early 2000s was highest in sub-Saharan Africa (570 cases per 
100,000 population), followed by the Pacific and the Indigenous populations of Australia and 
New Zealand (350 cases per 100,000 population) and south Central Asia (220 cases per 
100,000 population). In contrast, the estimated prevalence of RHD among children living in 
regions defined as established market economies (non-Indigenous Australian and New 
Zealand populations, Japan, Northern Europe, Southern Europe, Western Europe, and 
Northern America) was 30 per 100,000 population.  
Disparities in RHD prevalence across regions of the world and between specific population 
groups within these regions are believed to reflect disparities in socioeconomic and 
environmental conditions (RHD Australia 2012). In the case of Australia and New Zealand, 
disparities found in the prevalence of RHD among young children from Indigenous 
compared with non-Indigenous populations reveal a major health gap. 
How does the prevalence of RHD in the Northern Territory 
compare? 
In the light of these comparisons, findings from the Northern Territory reveal even greater 
disparity. In 2010, the overall prevalence of RHD in Aboriginal and Torres Strait Islander 
people in the Northern Territory was 26 times as high as that of their non-Indigenous 
counterparts (2,474 compared with 94 cases per 100,000 population). Further, between 2004 
and 2010 the age-adjusted prevalence of RHD in the Northern Territory increased from 555 
to 647 per 100,000 population (Table A2.1). 
7.3 Hospitalisations and deaths 
There is limited recent information on ARF and RHD hospitalisations in other countries. 
New Zealand data for 0–24 year olds for 2002–2006 show differences between some ethnic 
groups in hospitalisation rates for ARF and RHD (Craig et al. 2007). For example, ARF 
admission rates among people aged 0–24 over the 5 years were highest among those of 
Pacific and Maori ethnicity (62 and 29 per 100,000 population respectively), while those of 
European and Asian or Indian ethnicity had ARF admission rates of 1.3 per 100,000 
population. 
Based on studies from countries for which data were available, Carapetis et al. (2005b) 
estimated that worldwide there were at least 233,000 deaths due to RHD each year. 
However, it should be noted that it is difficult to obtain data on deaths from ARF and RHD 
in low- to middle-income countries, where these diseases are most common, because there 
are often no cause of death data collected or the data are not reliable (WHO 2005).  
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 Appendix A Detailed statistical tables 
A.1 Acute rheumatic fever 
Table A1.1: Acute rheumatic fever incidence in the Northern Territory, by age and sex, 2005–2010 
 Males  Females  Persons 
Age group 
(years) Number Per cent  Number Per cent  Number Per cent 
0–4 3 2.4  3 1.5  6 1.9 
5–14 77 62.6  106 54.6  183 57.7 
15–24 30 24.4  46 23.7  76 24.0 
25–34 8 6.5  21 10.8  29 9.1 
35+ 5 4.1  18 9.3  23 7.3 
Total 123 100.0  194 100.0  317 100.0 
Source: AIHW analysis of Northern Territory Rheumatic Heart Disease Program data. 
A.2 Rheumatic heart disease 
Table A2.1: Prevalence of rheumatic heart disease in the Northern Territory, by age, 2004 to 2010 
Age group 
(years) as at 31 
December  2004 2005 2006 2007 2008 2009 2010 
 Number of cases per 100,000 population(a) 
0–14 207.0 208.1 201.8 216.1 236.7 247.2 228.5 
15–24 854.4 861.0 905.1 930.7 923.5 907.1 863.7 
25–34 756.6 810.1 848.8 824.3 804.0 794.8 823.3 
35–44 682.3 728.1 733.0 795.8 832.8 832.3 847.5 
45–54 537.9 552.3 612.5 649.9 654.3 695.0 717.4 
55–64 538.6 538.2 580.9 604.4 545.1 540.4 537.1 
65+ 432.6 554.1 544.2 553.1 585.2 616.9 649.9 
Total 560.2 586.3 611.0 633.1 637.6 643.7 645.1 
ASR(b) 554.6 587.8 610.0 630.9 635.9 643.4 647.1 
(a) Age-specific rates calculated using the estimated resident population for the Northern Territory for each year. 
(b) Age-standardised to the 2001 Australian population. 
Source: AIHW analysis of Northern Territory Rheumatic Heart Disease Program data. 
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 Table A2.2: Deaths from rheumatic heart disease, by age and sex, 2007–2009(a) 
 Number of deaths  Deaths per 100,000 population 
Age group (years) Males Females Persons  Males Females Persons 
<35 14 17 31  0.1 0.1 0.1 
35–54 14 33 47  0.2 0.4 0.3 
55–64 35 40 75  1.0 1.1 1.0 
65–74 41 86 127  1.9 3.7 2.8 
75–84 110 221 331  8.5 13.6 11.3 
85+ 77 209 286  21.4 29.2 26.6 
Total 291 606 897  0.9 1.9 1.4 
ASR(b)     1.0 1.5 1.3 
Rate ratio per 100,000 
(Female rate÷Male rate)(c)       1.6 
Rate difference per 100,000   
(Female rate-Male rate)(d)       0.5 
(a) Cause of death data for 2009 are preliminary and subject to further revision. 
(b) Age-standardised to the 2001 Australian population. 
(c) The rate ratio was calculated by dividing the ASR for females by the ASR for males. The rate ratio was calculated before rounding ASRs to 
one decimal place. 
(d)  The rate difference was calculated by subtracting the ASR for males from the ASR for females. The rate difference was calculated before 
rounding ASRs to one decimal place. 
Source: Analysis of the AIHW National Mortality Database. 
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 Table A2.3: Deaths from rheumatic heart disease, by age and Indigenous status, 2004–2007 
 Deaths  Deaths per 100,000 population 
Age group (years) 
Indigenous 
Australians 
Non-Indigenous 
Australians  
Indigenous 
Australians 
Non-Indigenous 
Australians 
0-44 38 17  2.9 0.1 
45-64 18 57  8.9 0.5 
65+ 7 516  15.1 7.9 
Total 63 590  4.1 1.2 
ASR(a)    5.8 1.1 
Rate ratio per 100,000 
(Indigenous÷non-
Indigenous rate)(b)     5.2 
Rate difference per 
100,000 (Indigenous-
non-Indigenous rate)(c)     4.7 
(a) Age-standardised to the 2001 Australian population. 
(b) The rate ratio was calculated by dividing the ASR for Indigenous Australians by the ASR for other Australians. The rate ratio was  
calculated before rounding ASRs to one decimal place. 
(c)  The rate difference was calculated by subtracting the ASR for other Australians from the ASR for Indigenous Australians. The rate 
difference was calculated before rounding ASRs to one decimal place. 
Notes  
1. Based on data for deaths in persons usually resident in New South Wales, Queensland, Western Australia, South Australia and the 
Northern Territory. 
2. There were 8 records (1% of deaths) where Indigenous status was not stated and these cases were excluded from the analysis.  
Source: Analysis of the AIHW National Mortality Database. 
 
Table A2.4: Deaths from rheumatic heart disease, by state and territory of residence, 2005–2007 
   Deaths per 100,000 population 
State and territory of residence Number of deaths  Crude rate Age-standardised rate(a) 
NSW and ACT 252  1.2 1.1 
Vic 200  1.3 1.2 
Qld 151  1.2 1.2 
WA 91  1.5 1.5 
SA 67  1.4 1.2 
Tas 31  2.1 1.8 
NT 26  4.1 5.8 
Australia 818  1.3 1.2 
(a) Age-standardised to the 2001 Australian population. 
Source: Analysis of the AIHW National Mortality Database.  
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 Table A2.5: Deaths from rheumatic heart disease, by sex, 1979 to 2009 
 Number of deaths  Deaths per 100,000 population(a) 
Year Males Females Persons  Males Females Persons 
1979 149 282 431  2.0 3.1 2.6 
1980 156 281 437  2.1 3.1 2.7 
1981 153 227 380  2.1 2.4 2.3 
1982 153 254 407  1.9 2.6 2.3 
1983 135 246 381  1.7 2.4 2.1 
1984 127 287 414  1.5 2.8 2.3 
1985 149 280 429  2.0 2.7 2.3 
1986 130 264 394  1.5 2.5 2.1 
1987 139 253 392  1.7 2.3 2.0 
1988 147 258 405  1.6 2.3 2.0 
1989 146 279 425  1.6 2.4 2.1 
1990 131 229 360  1.5 1.9 1.7 
1991 132 255 387  1.4 2.1 1.8 
1992 116 240 356  1.2 1.9 1.6 
1993 114 248 362  1.2 1.9 1.6 
1994 110 229 339  1.1 1.8 1.5 
1995 92 175 267  0.9 1.3 1.1 
1996 97 159 256  0.9 1.1 1.1 
1997 108 213 321  1.5 2.2 1.9 
1998 67 144 211  0.9 1.4 1.2 
1999 84 175 259  1.1 1.7 1.4 
2000 99 162 261  1.3 1.5 1.4 
2001 79 157 236  1.0 1.4 1.2 
2002 81 188 269  0.9 1.7 1.3 
2003 97 189 286  1.1 1.6 1.4 
2004 80 169 249  0.9 1.4 1.2 
2005 100 183 283  1.1 1.5 1.3 
2006 87 194 281  0.9 1.5 1.3 
2007 85 169 254  0.9 1.3 1.1 
2008 109 222 331  1.1 1.6 1.4 
2009 97 215 312  0.9 1.6 1.3 
(a) Age-standardised to the 2001 Australian population. 
Notes 
1.  Death rates for 1979–1996 have been adjusted to ICD-10 standards using a comparability factor of 0.69. 
2.  Cause of death data for 2009 are preliminary and subject to revision by the Australian Bureau of Statistics (ABS). 
Sources: Analysis of the AIHW National Mortality Database.  
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 A.3 Hospitalisations for acute rheumatic fever and 
rheumatic heart disease 
Table A3.1: Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart 
disease by age and sex, 2009–10 
 Hospitalisations  Hospitalisations per 100,000 population 
Age group 
(years) Males Females Persons  Males Females Persons 
0–4 10 10 20  1.4 1.4 1.4 
5–9 31 42 73  4.5 6.4 5.4 
10–14 52 72 124  7.3 10.6 8.9 
15–19 42 28 70  5.6 3.9 4.8 
20–24 16 40 56  1.9 5.1 3.5 
25–34 34 80 114  2.2 5.2 3.7 
35–44 66 120 186  4.2 7.6 5.9 
45–54 81 139 220  5.4 9.1 7.3 
55–64 176 231 407  14.2 18.4 16.3 
65–74 272 363 635  35.2 45.2 40.3 
75–84 257 344 601  58.6 62.9 61.0 
85+ 43 117 160  33.8 46.9 42.4 
All ages 1,080 1,586 2,666  9.9 14.4 12.2 
ASR(a)     9.9 13.3 11.7 
Rate ratio per 100,000 
(Female rate÷Male rate)(b)      1.3 
Rate difference per 100,000   
(Female rate-Male rate)(c)      3.4 
(a)  Age-standardised to the 2001 Australian population. 
(b) The rate ratio was calculated by dividing the ASR for females by the ASR for males. The rate ratio was calculated before rounding ASRs to 
one decimal place. 
(c)  The rate difference was calculated by subtracting the ASR for males from the ASR for females. The rate difference was calculated before 
rounding ASRs to one decimal place. 
Note: Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart disease; excludes hospitalisations for unqualified 
 neonates, boarders and organ procurement. 
Source: AIHW National Hospital Morbidity Database. 
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 Table A3.2: Hospitalisations(a) with a principal diagnosis of acute rheumatic fever or rheumatic 
heart disease, by age and Indigenous status, between 2007–08 and 2009–10 
 Number of hospitalisations  Hospitalisations per 100,0000 population 
Age group (years) 
Indigenous 
Australians Other Australians(b)  
Indigenous 
Australians Other Australians(b) 
0–4 19 31  9.9 0.8 
5–9 142 57  76.1 1.5 
10–14 229 83  123.4 2.2 
15–19 118 91  67.1 2.3 
20–24 99 41  71.2 0.9 
25–34 148 127  68.0 1.5 
35–44 149 283  76.3 3.2 
45–54 90 625  63.8 7.4 
55–64 40 1,160  50.0 16.8 
65+ 31 4,021  61.5 49.0 
Total 1,065 6,519  68.1 10.8 
ASR(c)    66.9 10.0 
Rate ratio per 100,000  
(Indigenous÷Other)(d)     6.7 
Rate difference per 
100,000 (Indigenous-
Other)(e)     56.9 
(a) Based on patients usually resident in New South Wales, Victoria, Queensland, Western Australia, South Australia and the Northern 
Territory; excludes private hospitals in the NT. 
(b) Other Australians includes people whose Indigenous status was ‘Not stated’. 
(c)  Age-standardised to the 2001 Australian population. 
(d) The rate ratio was calculated by dividing the ASR for Indigenous Australians by the ASR for other Australians. The rate ratio was calculated 
before rounding ASRs to one decimal place. 
(e)  The rate difference was calculated by subtracting the ASR for other Australians from the ASR for Indigenous Australians. The rate 
difference was calculated before rounding ASRs to one decimal place. 
Note: Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart disease; excludes hospitalisations for unqualified 
 neonates, boarders and organ procurement. 
Source: AIHW National Hospital Morbidity Database.  
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 Table A3.3: Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart 
disease, by state and territory of residence, 2009–10 
State and territory of 
residence 
  Number of 
hospitalisations 
Hospitalisations per 100,000 
population(a) 
Crude rate per 100,000 
population 
NSW 643 8.4 9.0 
Vic 567 9.7 10.4 
Qld 649 14.6 14.8 
WA 270 11.9 11.9 
SA 209 10.8 12.9 
Tas 31 5.1 6.1 
ACT 20 6.3 5.6 
NT 206 86.4 90.2 
Australia(b) 2,666 11.7 12.2 
(a) Age-standardised to the 2001 Australian population. 
(b) Total does not equal subcategories due to incomplete reporting for the state of usual residence variable. 
Note: Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart disease; excludes hospitalisations for unqualified 
neonates, boarders and organ procurement. 
Source: AIHW National Hospital Morbidity Database. 
 
Table A3.4: Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart 
disease, by sex, 1999–00 to 2009–10 
 Number of hospitalisations  Hospitalisations per 100,000 population(a) 
Year Males Females Persons  Males Females Persons 
1999–00 827 1,364 2,191  9.3 14.0 11.7 
2000–01 819 1,248 2,067  9.1 12.5 10.8 
2001–02 893 1,363 2,256  9.6 13.4 11.5 
2002–03 916 1,380 2,296  9.7 13.3 11.5 
2003–04 915 1,377 2,292  9.5 13.0 11.3 
2004–05 1,005 1,443 2,448  10.2 13.3 11.8 
2005–06 977 1,533 2,510  9.8 14.0 11.9 
2006–07 1,054 1,507 2,561  10.3 13.4 11.9 
2007–08 1,187 1,514 2,701  11.3 13.2 12.3 
2008–09 1,073 1,541 2,614  10.1 13.2 11.7 
2009–10 1,080 1,586 2,666  9.9 13.3 11.7 
(a) Age-standardised to the 2001 Australian population. 
Note: Hospitalisations with a principal diagnosis of acute rheumatic fever or rheumatic heart disease; excludes hospitalisations for unqualified 
 neonates, boarders and organ procurement. 
Source: AIHW National Hospital Morbidity Database. 
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 Appendix B National data sources  
AIHW National Hospital Morbidity Database  
The AIHW’s National Hospital Morbidity Database (NHMD) is compiled from data supplied 
by the state and territory health authorities. It is a collection of electronic confidentialised 
summary records for separations (that is, episodes of admitted patient care) in almost all 
hospitals in Australia, including public acute hospitals, public psychiatric hospitals, private 
acute hospitals, private psychiatric hospitals and private free-standing day hospital facilities. 
Public sector hospitals that are not included are those not within the jurisdiction of a state or 
territory health authority (hospitals operated by the Department of Defence or correctional 
authorities, for example, and hospitals located in offshore territories).  
The data supplied to the NHMD are based on the National Minimum Data Set for Admitted 
Patient Care and include demographic, administrative and length of stay data, and data on 
the diagnoses of the patients, the procedures they underwent in hospital and external causes 
of injury and poisoning. 
The data are episode-based, and do not contain identifiers for individual people. As a result, 
it is not possible to count patients individually. A ‘hospitalisation’ or ‘separation’ refers to an 
episode of care for an admitted patient, which can be a total hospital stay (from admission to 
discharge, transfer or death), or a portion of a hospital stay beginning or ending in a change 
of type of care (for example, from acute to rehabilitation). 
Since 1998–99, diagnoses in the NHMD have been coded to the International Statistical 
Classification of Diseases and Related Health Problems, Tenth Revision, Australian 
Modification (ICD-10-AM) by clinical coders in each hospital, based on the diagnosis 
reported by a medical practitioner on discharge of the patient. The diagnosis is recorded for 
each hospital episode and is specific to that episode. The diagnosis-related hospital 
morbidity data presented in this report mainly cover 1 July 2007 to 30 June 2010 but trends 
are reported for 1 July 1999 to 30 June 2010. In 2007–08, diagnoses and external causes of 
injury were recorded using the fifth edition of the International Statistical Classification of 
Diseases and Related Health Problems, 10th Revision, Australian Modification (ICD-10-AM) 
(NCCH 2006), while in 2008–09 and 2009–10, diagnoses and external causes of injury were 
recorded using the sixth edition of the ICD-10-AM (NCCH 2008). 
Most of the hospitalisations data presented in this report relate to separations with a 
principal diagnosis of ARF (ICD-10-AM I00–I02) or RHD (ICD-10-AM I05–I09). The principal 
diagnosis is the diagnosis established after study to be chiefly responsible for the episode of 
admitted patient care.  
Separations for which the care type was reported as Newborn without qualified days, and 
records for Hospital boarders and Posthumous organ procurement have been excluded from 
statistics on hospital separations reported here. 
Procedures for 2007–08 were classified, coded and reported to the National Hospital 
Morbidity Database by all states and territories, using the fifth edition of the Australian 
Classification of Health Interventions (ACHI) (NCCH 2006), while procedures for 2008–09 
and 2009–10 were classified, coded and reported using the sixth edition of the ACHI (NCCH 
2008). 
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 The ACHI heart valve surgery procedure codes used in conjunction with a principal 
diagnosis of ARF or RHD this report were: 
• Aortic Valve (Blocks 621, 622, 623, 624): 38456-10, 38483-00, 38270-01, 38480-00, 38481-00, 
38488-00, 38488-01, 38489-00, 38489-01, 38456-15, 38653-04, 38475-02, 38477-02. 
• Mitral valve (Blocks 625, 626, 627, 628, 629, 630): 38487-00, 38485-01, 38270-02, 38480-01, 
38481-01, 38475-00, 38477-00, 38488-02, 38488-03, 38489-02, 38485-00, 38456-16, 38653-05. 
• Tricuspid valve (Blocks 631, 632, 633, 634, 635): 38456-11, 38480-02, 38481-02, 38475-01, 
38477-01, 38488-04, 38488-05, 38489-03, 38456-17, 38653-06. 
• Pulmonary valve (Blocks 636, 637, 638): 38456-01, 38270-03, 38488-06, 38488-07, 38489-04, 
38489-05, 38456-18, 38653-07. 
One or more procedures can be reported for each separation, but procedures are not 
undertaken for all hospital admissions, so only some of the separation records include 
procedure data. 
The data quality statement for the AIHW National Hospital Morbidity Database can be 
found at on the AIHW’s Metadata Online Registry (METeOR)— 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/511338>. 
AIHW National Mortality Database 
The mortality data used in this report were provided by the Registries of Births, Deaths and 
Marriages, the Australian Bureau of Statistics and the National Coronial Information System. 
These data are maintained at the Australian Institute of Health and Welfare in the National 
Mortality Database. 
The National Mortality Database contains coded causes of death from the information 
documented by the medical practitioner certifying the death or by a coroner. Registration of 
deaths is the responsibility of the state and territory Registrars of Births, Deaths and 
Marriages. These data are then collated and coded by the Australian Bureau of Statistics 
(ABS) to the International Statistical Classification of Diseases and Related Health. Since 
1997, deaths in Australia have been coded to the 10th Revision of the International 
Classification of Diseases (ICD-10). 
Data on deaths from ARF (ICD-10 I00–I02) and RHD (ICD-10 I05–I09) in this report have 
been identified based on the ‘underlying cause’—the disease or injury that initiated the train 
of events leading directly to death, or the circumstances of the accident or violence that 
produced the fatal injury. In Australia, the underlying cause is derived from information on 
the death certificate, using an automated process.  
In addition, the death data presented in this report have been collated according to the year of 
registration of the death and cover the period 1 January 1979 to 31 December 2009. 
The data quality statements underpinning the AIHW National Mortality Database are in the 
following ABS publications: ABS Quality declaration summary for Causes of death 2010 (ABS 
cat. no. 3303.0) 
<http://www.abs.gov.au/Ausstats/abs@.nsf/0/D4A300EE1E04AA43CA2576E800156A24?
OpenDocument> and ABS Quality declaration summary for Deaths, Australia 2010 (ABS cat. 
no. 3302.0) 
<http://www.abs.gov.au/Ausstats/abs@.nsf/0/9FD0E6AAA0BB3388CA25750B000E3CF5?
OpenDocument>. 
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 AIHW Disease Expenditure Database  
A comprehensive database that allocates health expenditure estimates by disease category, 
area of expenditure, and by age and sex.  
This report provides direct health expenditure on ARF and RHD under three categories: 
• Admitted patient hospital services covering the expenditure on services provided to an 
admitted patient, including expenditure on medical services delivered to private 
admitted patients in hospitals. 
• Prescription pharmaceuticals including prescriptions subsidised under government 
schemes (for example, the Pharmaceutical Benefits Scheme and Repatriation 
Pharmaceutical Benefits Scheme), private prescriptions and under co-payment 
prescriptions. Pharmaceuticals dispensed in hospitals were included in the estimates of 
hospital costs. 
• Out-of hospital medical services comprising medical services primarily funded under 
the Medical Benefits Schedule, such as primary health visits, pathology and specialist 
services. Practice Incentive Payments are also included. In addition, medical services 
funded by Department of Veteran’s Affairs, compulsory motor vehicle third party 
insurance, workers compensation insurance, private health insurance funds, the 
Australian Government premium rebates allocated to medical services as well as 
Medicare co-payments and other out-of-pocket payments are all included. In hospital 
medical expenditure for private patients was not included here but as part of admitted 
patient hospital services.  
The data quality statement for the AIHW Disease Expenditure Database 2008–09 can be 
found at on the AIHW’s Metadata Online Registry (METeOR)— 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/512599 >. 
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 Appendix C Data and statistical methods 
Reporting Indigenous deaths data 
The ABS has assessed the quality of Indigenous identification in death registration data by 
state and territory in the Census Data Enhancement Indigenous Mortality Quality Study. 
This study involved linking Census records with death registration records to examine 
differences in reporting of Indigenous status across two data sets. This assessment indicates 
that the Indigenous identification rate is 87% or higher in New South Wales, Queensland, 
Western Australia and the Northern Territory, and about 65% for the remaining 
jurisdictions. Historically, Indigenous identification in South Australia, Western Australia 
and the Northern Territory has been of sufficient quality to include in analyses from 1991 
onwards. Queensland was included in analysis from 1998 onwards and, in 2010, a decision 
was made to include data from New South Wales from 2001 onwards. Therefore, analysis of 
deaths data by Indigenous status between 2004 and 2007 in this report are based on data 
where the deceased’s state of residence was New South Wales, Queensland, Western 
Australia, South Australia or the Northern Territory. 
Reporting Indigenous hospitalisations data 
In February 2010, the AIHW released a report on the quality of Indigenous identification in 
hospital separations data (AIHW 2010). The report recommended that, from 2004–05, the 
level of Indigenous identification in hospitalisations data was acceptable for analysis 
purposes (that is, the level of Indigenous identification was 80% or greater) for data from 
New South Wales, Victoria, Queensland, Western Australia, South Australia and the 
Northern Territory (public hospitals only). Data are reported based on the state or territory 
of the patient’s usual residence for these six jurisdictions. As at June 2010, the proportion of 
the Indigenous population covered by these six jurisdictions was 96% (ABS 2009). 
Populations used in this report 
Population data are used in this report to calculate rates. The population data used are 
estimated resident populations (ERPs) derived from the ABS Census of Population and 
Housing. ERPs adjust Census data to add people missed by the Census and people overseas 
on Census night, and to remove overseas visitors. In between Census years, the ERPs are 
updated using indicators of population change such as deaths, births and net migration. The 
ERPs used in this report are based on the 2006 Census. 
For death data, a rate was calculated for a calendar year and the population used was the 
ERP as reported at 30 June of that year. For hospital data, a rate was calculated for a financial 
year and the population used was the ERP for 31 December of the year in the middle span. 
For example, to calculate the hospitalisation rate of the 2009–10 financial year, the population 
for 31 December 2009 was used. 
Throughout the report, rates of deaths and hospitalisations are age-standardised. In these 
cases, the standard population used to calculate the age-standardised rate was the Australian 
ERP as at 30 June 2001. 
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 Indigenous population 
Australia’s Indigenous population is calculated from the Census, and uses ERPs as described 
above. Four years of data (2004 to 2007) were combined for the analyses of ARF and RHD 
deaths by Indigenous status to overcome the small numbers and year-to-year variability in 
deaths. For these analyses, the Indigenous population reference years were combined from 
30 June 2004 to 30 June 2007.  
For hospitalisations, 3 years of data from 2007–08 to 2009–10 were combined due to small 
numbers. The Indigenous ERP for each financial year was calculated by taking the average of 
the 30 June Indigenous ERPs. For example, to derive the Indigenous ERP as at 31 of 
December 2009, the Indigenous ERPs (for the relevant states and territories) at 30 June 2009 
and at 30 June 2010 were summed and averaged. To get the equivalent ERP for Other 
Australians, the derived Indigenous ERP was subtracted from the Australia-wide ERP 
(selecting only the relevant states and territories) at 31 December for a given year.  
Crude and age-specific rates  
Crude rates and age-specific rates are calculated by dividing the number of events in a 
specified time period by the total number of individuals in the population (in the same age 
group). Age-specific rates are not age-standardised.  
Age-standardised rates  
Age-standardisation is a technique used to take account of the effect of differences in 
population age structures when comparing rates across different population groups (such as 
men and women) or across time. The direct method of standardisation was used to calculate 
age-standardised rates (ASRs) in this report, including ASRs for length of stay.  
Direct age-standardisation  
Age-standardised proportions have been calculated using the following formula:  
 
Age-standardised proportion (ASR) = Σ(ri Pi)/ΣPi  
 
where:  
ri  is the sex- and age group-specific rate for sex and age group i in the population being 
studied  
Pi  is the population of age group i in the standard population.  
 
The standard population used was the Australian estimated resident population as at 30 
June 2001. 
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 Appendix D Diagnosis guidelines  
Table D1: The 2012 updated Australian guidelines for the diagnosis of ARF 
 High-risk groups(a) All other groups 
Definite initial episode of ARF 2 major or 1 major and 2 minor manifestations plus evidence of a preceding GAS 
infection(b) 
Definite recurrent episode of ARF in a 
patient with known past ARF or RHD 
2 major or 1 major and 1 minor or 3 minor manifestations plus evidence of a 
preceding GAS infection(b) 
Probable ARF (first episode or 
recurrence) 
A clinical presentation that falls short by either one major or one minor 
manifestation, or the absence of streptococcal serology results, but one in which 
ARF is considered the most likely diagnosis. Such cases should be further 
categorised according to the level of confidence with which the diagnosis is made:  
Highly suspected ARF 
Uncertain ARF 
Major manifestations Carditis (including subclinical evidence 
of rheumatic valvulitis on 
echocardiogram) 
Polyarthritis(c) or aseptic mono-arthritis or 
polyarthralgia 
Chorea(d) 
Erythema marginatum(e) 
Subcutaneous nodules 
 
Carditis (including subclinical evidence 
of rheumatic valvulitis on 
echocardiogram) 
Polyarthritis(c)  
 
Chorea(d) 
Erythema marginatum(e) 
Subcutaneous nodules 
 
Minor manifestations Monoarthralgia 
Fever(f) 
ESR(h) ≥30 mm/hor CRP(h) ≥30 mg/L 
Prolonged P-R interval on ECG(g) 
 
Fever(f) 
Polyarthralgia or aseptic mono-arthritis  
ESR(h) ≥30 mm/h or CRP(h) ≥ 30 mg/L 
Prolonged P-R interval on ECG(g)(h) 
(a) High-risk groups are those living in communities with high rates of ARF (incidence>30/100,000 per year in 5–14 year olds) or RHD (all-age 
prevalence >2/1000). Aboriginal people and Torres Strait Islanders living in rural or remote settings are known to be at high risk. Data are 
not available for other populations, but Aboriginal and Torres Strait Islander people living in urban settings, Maoris and Pacific Islanders, 
and potentially immigrants from developing countries, may also be at high risk.  
(b) Elevated or rising antisreptolysin O or other streptococcal antibody, or a positive throat culture or rapid antigen test for GAS. 
(c) A definite history of arthritis is sufficient to satisfy this manifestation. Note that if polyarthritis is present as a major manifestation, 
polyarthralgia or aseptic mono-arthritis cannot be considered an additional minor manifestation in the same person. 
(d) Chorea does not require other manifestations or evidence of preceding GAS infection, provided other causes of Chorea are excluded.  
(e) Care should be taken not to label other rashes, particularly non-specific viral exanthemas, as erythema marginatum. 
(f) Oral, tympanic or rectal temperature ≥38°C on admission, or a reliably reported fever documented during the current illness.  
(g) If carditis is present as a major manifestation, a prolonged P-R interval cannot be considered an additional minor manifestation 
(h) CRP, C-reactive protein; ECG, electrocardiogram; ESR, erythrocyte sedimentation rate. 
Source: RHD Australia 2012. 
 
 
 
 
 
 Rheumatic heart disease and acute rheumatic fever in Australia: 1996–2012 45 
 Table D2: The World Heart Federation criteria for echocardiographic diagnosis of RHD 
1. Echocardiographic criteria for individuals ≤20 years of age 
Definite RHD (either A, B, C or D): 
(A) Pathological MR(a) and at least two morphological features of RHD of the mitral valve 
(B) Mitral stenosis (MS)(b) mean gradient ≥4 mmHg (note: congenital mitral valve anomalies must be excluded) 
(C) Pathological AR(c) and at least two morphological features of RHD of the aortic valve (note: bicuspid aortic 
valve and dilated aortic root must be excluded) 
(D) Borderline disease of both the aortic and mitral valve(d) 
 
Borderline RHD (either A, B or C): 
(A) At least two morphological features of RHD of the mitral valve without pathological MR or MS 
(B) Pathological MR 
(C) Pathological AR 
 
Normal echocardiographic findings (all of A, B, C and D): 
(A) Mitral regurgitation (MR) that does not meet all four Doppler criteria (physiological MR) 
(B) Aortic regurgitation (AR) that does not meet all four Doppler criteria (physiological AR) 
(C) An isolated morphological feature of RHD of the mitral valve (e.g. valvular thickening), without any 
associated pathological stenosis or regurgitation 
(D) Morphological feature of RHD of the aortic valve (e.g. valvular thickening), without any associated 
pathological stenosis or regurgitation 
 
2. Echocardiographic criteria for individuals >20 years of age 
Definite RHD (either A, B, C or D): 
(A) Pathological MR and at least two morphological features of RHD of the mitral valve 
(B) MS mean gradient ≥4 mmHg (note: congenital mitral valve anomalies must be excluded) 
(C) Pathological AR and at least two morphological features of RHD of the aortic valve in individuals <35 
years of age only (note: hypertension, bicuspid aortic valve and dilated aortic root must be excluded) 
(D) Pathological AR and at least two morphological features of RHD of the mitral valve 
 
(a) Mitral regurgitation 
(b) Mitral stenosis 
(c) Aortic regurgitation 
(d) Combined AR and MR in high-prevalence regions and in the absence of congenital heart disease is regarded as rheumatic. 
Source: RHD Australia 2012. 
 
 
46 Rheumatic heart disease and acute rheumatic fever in Australia: 1996–2012 
 
 Glossary 
Aboriginal or Torres Strait Islander: A person of Aboriginal and/or Torres Strait Islander 
descent who identifies as an Aboriginal and/or Torres Strait Islander and is accepted as such 
by the community in which he or she lives. 
age-specific rate: A rate for a specific age group. The numerator and denominator relate to 
the same age group. 
age-standardisation: A method of removing the influence of age when comparing 
populations with different age structures. This is usually necessary because the rates of many 
diseases vary strongly (usually increasing) with age. The age structures of the different 
populations are converted to the same ‘standard’ structure, the disease rates that would have 
occurred with that structure are then calculated and compared. 
associated causes of death: Causes, other than the underlying cause, that were instrumental 
in causing death. They encompass conditions that intervened or significantly contributed to 
the death. Associated causes include: 
• the immediate (or direct) cause; that is, the condition that occurred immediately before 
death or closest to the time of death 
• all intermediate (or intervening) causes; that is, the conditions that occurred between the 
underlying and immediate causes 
• all significant contributing causes; that is, all significant conditions contributing to the 
death but which did not bring about the underlying cause, including significant pre-
existing conditions. 
cardiovascular disease (CVD): Any disease of the circulatory system, namely the heart 
(cardio) or blood vessels (vascular). Includes heart attack, angina, stroke and peripheral vascular 
disease. CVD is also known as circulatory disease. 
cause of death: Causes of death are defined (in 1967, by the World Health Assembly) as ‘all 
those diseases, morbid conditions or injuries which either resulted in or contributed to death 
and the circumstances of the accident or violence which produced any such injuries’ (WHO 
2009). This definition aims to capture all the relevant information on the death certificate 
thereby reducing bias that might arise if, for example, the certifier selected some conditions for 
entry and rejected others. The causes of death, as documented on the death certificate, should 
not include symptoms or the mode of dying. See also underlying cause of death. 
communicable diseases (infectious diseases): Diseases or illnesses due to infectious 
organisms or their toxic products. Communication may occur directly or indirectly through 
contact with other humans, animals or other environments that harbour the organism. 
crude death rate: The number of deaths in a given period divided by the size of the 
corresponding population indexed to 100,000. 
disease: A physical or mental disturbance involving symptoms (such as pain or feeling 
unwell), dysfunction or tissue damage, especially if these symptoms and signs form a 
recognisable clinical pattern. 
hospitalisation: See separation. 
incidence: The number of new cases (of an illness or event, and so on) occurring during a 
given period. Compare with prevalence. 
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 International Classification of Diseases: The World Health Organization’s internationally 
accepted classification of death and disease. The 10th Revision (ICD-10) is currently in use 
(WHO 2009). In this report, causes of death classified before 1979 under previous revisions 
have been reclassified to ICD-10 by the AIHW. ICD-10-AM is the Australian modification of 
ICD-10, used for diagnoses and procedures recorded for patients admitted to hospitals. 
morbidity: Refers to ill health in an individual and to levels of ill health in a population or 
group. 
Other Australians People who are not of Aboriginal or Torres Strait Islander descent, or 
whose status is not known.  
prevalence: The number or proportion (of cases, instances, and so forth) present in a 
population at a given time. Compare with incidence. 
principal diagnosis: The diagnosis listed in hospital records to describe the problem that 
was chiefly responsible for the patient’s episode of care in hospital. 
private hospital: A privately owned and operated institution, catering for patients who are 
treated by a doctor of their own choice. Patients are charged fees for accommodation and 
other services provided by the hospital and relevant medical and allied health practitioners. 
public hospital: A hospital controlled by a state or territory health authority. In Australia 
public hospitals offer free diagnostic services, treatment, care and accommodation to all 
Australians who need them. 
rheumatic fever: An acute, serious disease that affects mainly children and young adults and 
can damage the heart valves, the heart muscle and its lining, the joints and the brain. Is 
brought on by a reaction to a throat infection by a particular bacterium. Now very rare in the 
non-Indigenous population, it is still at unacceptably high levels among Indigenous 
Australians living in remote areas. See rheumatic heart disease. 
rheumatic heart disease (RHD): Chronic disease from damaged heart valves caused by 
earlier attack(s) of rheumatic fever. 
risk factor: Any factor that represents a greater risk of a health disorder or other unwanted 
condition or event. Some risk factors are regarded as causes of disease, others are not 
necessarily so. Along with their opposites, protective factors, risk factors are known as 
determinants. 
separation: An episode of care for an admitted patient, which can be a total hospital stay 
(from admission to discharge, transfer or death) or a portion of a hospital stay beginning or 
ending in a change of type of care (for example, from acute to rehabilitation). Separation also 
means the process by which an admitted patient completes an episode of care by being 
discharged, dying, transferring to another hospital or changing type of care. 
underlying cause of death: The disease or injury that initiated the train of events leading 
directly to death, or the circumstances of the accident or violence that produced the fatal 
injury. Compare with associated causes of death. 
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This report examines and presents a range of data on 
acute rheumatic fever (ARF) and rheumatic heart disease 
(RHD) in Australia. It shows that ARF now occurs almost 
exclusively in Aboriginal and Torres Strait Islander 
people, and that the prevalence of RHD is much higher 
among Indigenous people than other Australians. 
Aboriginal and Torres Strait Islander people are also 
considerably more likely to be hospitalised with ARF or 
RHD, and to die from RHD.
